defects were compared across metastatic sites by Pearson's Chisquared test.
INTRODUCTION AND OBJECTIVES:
A risk stratification of Nþ prostate cancer (PCa) patients according to tumor characteristics was recently proposed (Abdollah et al. JCO 2014) . The aim of this study was to assess whether the rate of other cause mortality (OCM) differs in Nþ PCa patients according to these 5 risk-groups, after accounting for the risk of cancer specific mortality (CSM). This would allow to improve patient stratification and to identify candidates for additional therapies.
METHODS: We evaluated 1,312 Nþ PCa patients treated with radical prostatectomy and pelvic lymph node dissection at two tertiary referral centers between 1988 and 2014. Patients were stratified into the 5 established risk-groups: very low-risk (2 Nþ, and Gleason score 6); low-risk (2 Nþ, Gleason score 7-10, pT2/pT3a and negative surgical margins); intermediate-risk (2 Nþ, Gleason score 7-10 and pT3b/pT4 or SMþ); high-risk (3-4 Nþ); very high-risk (>4 Nþ). Poisson smoothed cumulative incidence methods were used to assess 8-year OCM according to risk groups, after accounting for the risk of CSM. The same analyses were performed among men who experienced BCR after RP (n¼ 633, 48.2%).
RESULTS: The median follow-up after RP was 82 months (IQR 37.1-147). During the study period, 18.1% of men died from other causes and 14.6% died from PCa. The leading cause of death at 8-year was OCM in the very low and low risk groups (12.6 and 8.3% vs. 2.5 and 7.6% for CSM, respectively). Conversely, CSM was the main cause of death in the remaining groups (Fig 1a) . When the same analyses were repeated in men who had BCR after RP, CSM was the leading cause of death in all risk-groups except in very low-risk patients, where the 8-year OCM and CSM were similar (5.9 and 5.8%, respectively; Fig. 1b 
Transrectal ultrasoundguided prostate biopsies (TRUS-Bx) have a high false-negative rate, and thus men with a negative TRUS-Bx frequently undergo repeat biopsies leading to subsequent diagnoses of prostate cancer (PCa). Long-term outcome data on such patients is lacking, as previous studies have only reported the short-term rates of PCa diagnosis in small cohorts of men with a negative TRUS-Bx. Our objective was to determine both the long-term rates of PCa diagnosis and all-cause mortality in a large, population-based cohort of men with a single negative TRUS-Bx.
METHODS: This was a retrospective, population-based study of 124,067 men who had an initially negative TRUS-Bx in Ontario, Canada between April 1994 and March 2015. All included men were older than 40 years and had no prior history of PCa. Using data from the Ontario Health Insurance Plan, Ontario Cancer Care Registry, and Registered Persons Database, housed at the Institute of Clinical and Evaluative Sciences, we were able to determine the 5, 10, 15, and 20 year rates of PCa diagnosis and all-cause mortality in such men.
RESULTS: Mean age at date of first negative TRUS-Bx was 63.55 years (SD¼8.75). Total follow-up time was 974986.07 person-years, with mean follow-up per patient at 7.86 years (SD¼5.37). The total number of subsequent PCa diagnoses was 21,869, accounting for an incidence rate of 22.25 per 1000 person-years. The 5, 10, 15, and 20-year rates of PCa diagnosis were 0.130, 0.187, 0.220, and 0.239, respectively. The total number of deaths in our cohort was 21,375, accounting for a death incidence rate of 21.92 per 1000 person-years. The 5, 10, 15, and 20-year all-cause mortality rates were 0.068, 0.155, 0.260, and 0.380, respectively.
CONCLUSIONS: Based upon these long-term populationbased data, a significant proportion of men with an initially negative TRUS-Bx subsequently receive a diagnosis of PCa, with risk of diagnosis continuously rising. These data suggest that long term follow up of at risk men is warranted. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e57
Source INTRODUCTION AND OBJECTIVES: Accurate assessment of life expectancy (LE) is critical to appropriate case selection for men with prostate cancer. We previously reported the age-adjusted Prostate Cancer Comorbidity Index (PCCI), a LE prediction tool that uses a weighted score incorporating age and comorbidities to estimate 2, 5, and 10-year mortality in men with prostate cancer. We sought to operationalize the PCCI for clinical application using claims data and externally validate it across a nationally representative sample. We then compared its ability to identify patients at risk for overtreatment with the age-adjusted Charlson comorbidity index.
METHODS: We sampled 181,209 men with prostate cancer diagnosed from 2000 to 2011 in the Veterans Affairs healthcare system. We used claims data within 12 months of biopsy to determine comorbidities at diagnosis. We used Kaplan-Meier analysis to plot overall survival and multivariable Cox proportional hazards analysis to assess risk discrimination between PCCI and Charlson score subgroups. We then compared the number of men with <10-year LE who were treated with surgery or radiation between the two indices.
RESULTS: Kaplan-Meier analysis showed a stepwise increase in risk of overall mortality with increasing PCCI score (Figure) . Ten-year mortality among men with PCCI scores of 1-2, 3-4, 5-6, 7-9, and 10þ was 26%, 36%, 41%, 52%, and 69%, respectively. Multivariable models showed excellent risk discrimination with hazard ratios of 1.22 (95%CI 1.18-1.27), 1.69 (95%CI 1.61-1.76), 2.08 (95%CI 2.00-2.17), 2.88 (95%CI 2.76-3.00), 4.50 (95%CI 4.32-4.69) for PCCI scores of 1-2, 3-4, 5-6, 7-9, and 10þ, respectively. The PCCI identified 30,610 men with LE <10 years (<50% median survival at 10 years) vs. 25,455 men in the Charlson index. Furthermore, the PCCI identified significantly more men with <10-year LE who were overtreated with surgery or radiation compared with the Charlson index: 12,531 (41%) vs. 7,098 (28%) (p<0.0001).
CONCLUSIONS: The age-adjusted Prostate Cancer Specific Comorbidity Index (PCCI) showed excellent prognostic utility across a nationally representative sample of men with prostate cancer. It was superior to the Charlson index in identifying men at risk for overtreatment due to limited LE. We assessed the temporal trends in the delay-and age-adjusted incidence (per 100,000 US men) of metastatic PCa, using annual percentage change (APC; weighted least squares method). Analyses were stratified by year groups (2004-2008 vs. 2009-2013) and age categories (45-74 vs 75 and above). We also performed sensitivity analyses using JoinPoint regression to identify the time points associated with a change in the incidence of metastatic PCa, overall and stratified by aforementioned age groups. RESULTS: Overall, there was a non-significant change in incidence between 2004-2008, but a significant increase between 2009-2013 (APC 2.9%, p¼0.01). For men aged 45-74, metastatic PCa incidence increased by 2.6% per year between 2009-2013 (p¼0.008, Figure 1b ). Men aged 75 showed a significant decline in the incidence of metastatic PCa for 2004-2008 (APC -2.5%, p¼0.02), and a nonsignificant increase for 2009-2013 (APC 3.2%, p¼0.1; Figure 1b ). JoinPoint regression analyses showed similar findings, with a significant increase in metastatic PCa incidence starting in 2009 overall and for men aged 45-74 (Figures 1c-e) . CONCLUSIONS: Our results suggest an increase in the incidence of metastatic PCa in the US, beginning in the more contemporary time period (2009-13) for men aged 45 and above. Future large scale studies are warranted to validate our findings, identify the causes and understand its implications on health care policy for US men.
